- Corrigendum to: Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
-
Kumar A, Kumar N, Pattanayak A, Kumar A, Palavesam S, Nagaraju PM, Das R
- KMID: 2563556
- Acute Crit Care.
- 2024 Nov;39(4):652-653.
- doi: 10.4266/acc.2023.00983.e1
-
- CITED
-
- Close
- SHARE
-
- Close
- Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study
-
Kumar A, Kumar N, Pattanayak A, Kumar A, Palavesam S, Manigowdanahundi Nagaraju P, Das R
- KMID: 2557239
- Acute Crit Care.
- 2024 May;39(2):234-242.
- doi: 10.4266/acc.2023.00983
Background: Itolizumab downregulates the synthesis of proinflammatory cytokines and adhesion molecules by inhibiting CD6 leading to lower levels of interferon-γ, interleukin-6, and tumor necrotic factor-α and reduced T-cell infiltration at... -
- CITED
-
- Close
- SHARE
-
- Close
